Cytokinetics Inc. (CYTK) is a publicly traded Healthcare sector company. As of October 14, 2026, CYTK trades at $62.48 with a market cap of $8.73B and a P/E ratio of -9.00. CYTK moved -1.82% today. Year to date, CYTK is -0.18%; over the trailing twelve months it is +3.41%. Its 52-week range spans $29.31 to $88.31. Analyst consensus is strong buy with an average price target of $110.33. Rallies surfaces CYTK's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for CYTK, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $62.48 |
| Market Cap | $8.73B |
| P/E Ratio | -9.00 |
| EPS | $-7.22 |
| Dividend Yield | 0.00% |
| 52-Week High | $88.31 |
| 52-Week Low | $29.31 |
| Volume | 1.56M |
| Avg Volume | 0 |
| Revenue (TTM) | $67.67M |
| Net Income | $-894.00M |
| Gross Margin | 0.00% |
16 analysts cover CYTK: 0 strong buy, 15 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $110.33.